Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic Disease

Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00569361

Enrollment

Registered

2007-12-07

Start date

2004-11-30

Completion date

2005-10-31

Last updated

2009-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Keywords

allergic rhinitis to dust mite, allergic rhinitis associated with bronchial hyperreactivity, allergic rhinitis associated with asthma

Brief summary

Using a human pangenomic microarray, the researchers established expression profiles of nasal epithelial cells, collected by brushing of patients belonging to one of four distinct groups: 1. allergic rhinitis to dust mite (AR) isolated (n=12), 2. AR associated with bronchial hyperreactivity (n=12), 3. AR associated with asthma (n=14), 4. control (n=14).

Detailed description

Context: Asthma is the most frequent chronic disease in childhood. Allergic rhinitis has been described as a risk factor to develop asthma. The objective of the study was to evaluate the contribution of the respiratory epithelium to development of allergic rhinitis and asthma and to identify the molecular mechanisms driving rhinitis toward asthma. Methods: Using a human pangenomic microarray, we established expression profiles of nasal epithelial cells, collected by brushing of patients belonging to one of four distinct children 2 to 18 years of age groups: 1. allergic rhinitis to dust mite (AR) isolated (n=12), 2. AR associated with bronchial hyperreactivity (n=12), 3. AR associated with asthma (n=14), 4. control (n=14).

Interventions

PROCEDURECollection of nasal epithelial cells

Collection of nasal epithelial cells by brushing

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to 17 Years

Healthy volunteers

Inclusion criteria

Patients: * Patients between 6 and 17 years old * Patients with allergic rhinitis Witness: * Patients between 6 and 17 years old * Patients without allergic rhinitis and asthma

Exclusion criteria

* Rhino-bronchitis infection dated from less than 15 days * Patients younger than 6 or older than 17 years

Design outcomes

Primary

Measure	Time frame
Transcriptome analysis: genes statistically modulated between groups, predictive biomarkers allowing correct classification of groups	At the sample time

Secondary

Measure	Time frame
Validation with other techniques: Q-PCR	At the sample time

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026